Uses of imidazolidine and composition comprising imidazolidine

A technology of mizoribine and its composition, which is applied in the field of ophthalmic disease treatment, and can solve problems such as uneven treatment effects

Active Publication Date: 2021-01-15
EYE MEDICAL XIAMEN BIOTECHNOLOGY CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In terms of treatment, it is advocated to treat the cause, including correction of ametropia, surgical adjustment of extraocular muscles, extraocular muscle training, etc., but the treatment effect is uneven, and there is no good clinical medicine for relieving visual fatigue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of imidazolidine and composition comprising imidazolidine
  • Uses of imidazolidine and composition comprising imidazolidine
  • Uses of imidazolidine and composition comprising imidazolidine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0168] The preparation of embodiment 1 mizoribine eye drops

[0169] formula:

[0170] Mizoribine 0.50g Benzalkonium chloride 0.03g Sodium chloride 8.30g 0.1mol / L hydrochloric acid 30mL Water for Injection Dilute to 1000mL

[0171] Preparation Process:

[0172] 1. Accurately weigh 0.50g of midazoribine, 0.03g of benzalkonium chloride, 8.30g of sodium chloride, 30mL of 0.1mol / L hydrochloric acid, add 200mL of water for injection to dissolve, stir evenly, and dilute to 1000mL with water for injection to obtain The medicinal liquid, the pH of the medicinal liquid is 6.8-7.0.

[0173] 2. Filter the above solution once through a 0.45 μm microporous membrane, and then twice through a 0.22 μm microporous membrane.

[0174] 3. After the drug solution is qualified, fill 5.0mL of the above drug solution into a 5mL sterilized single-dose packaging plastic container in a grade A environment, and seal it to obtain the finished product.

Embodiment 2

[0175] The preparation of embodiment 2 Mizoribine eye drops

[0176] formula:

[0177] Mizoribine 0.50g Chlorhexidine acetate 0.05g Sodium dihydrogen phosphate 7.20g Disodium phosphate 0.95g Sodium chloride 4.79g Water for Injection Dilute to 1000mL

[0178] Preparation Process:

[0179] 1. Accurately weigh 0.50g of midazoribine, add 300mL of water for injection to dissolve it, and obtain solution ① for later use.

[0180] 2. Accurately weigh 0.05g of chlorhexidine acetate, 7.20g of sodium dihydrogen phosphate, 0.95g of disodium hydrogen phosphate, and 4.79g of sodium chloride, add 200mL of water for injection to dissolve, stir and mix evenly to obtain a solution② spare.

[0181] 3. Mix the solution ① and the solution ②, stir evenly, and dilute the volume to 1000mL with water for injection to obtain a medicinal solution, the pH of which is 6.8-7.0.

[0182] 4. Filter the above medicinal solution once through a 0.45 μm microporou...

Embodiment 3

[0184] The preparation of embodiment 3 mizoribine eye drops

[0185] formula:

[0186] Mizoribine 0.50g Benzalkonium Bromide 0.03g Sodium dihydrogen phosphate 6.40g Disodium phosphate 1.89g Sodium chloride 4.72g Disodium edetate 0.10g Water for Injection Dilute to 1000mL

[0187] Preparation Process:

[0188] 1. Accurately weigh 0.50g midazoribine, 0.03g benzalkonium bromide, 6.40g sodium dihydrogen phosphate, 1.89g disodium hydrogen phosphate, 4.72g sodium chloride, 0.10g disodium edetate, add 200mL Dissolve in water for injection, stir evenly, and dilute to 1000 mL with water for injection to obtain a medicinal solution, the pH of which is 6.8-7.0.

[0189] 2. Filter the medicinal solution prepared above through a 0.45 μm microporous membrane once, and then through a 0.22 μm microporous membrane once.

[0190] 3. The filtered liquid medicine is sterilized at 121° C. for 8 minutes by autoclaving, and then cooled.

[0191]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to uses of imidazolidine and a composition containing the imidazolidine, and particularly provides uses of the imidazolidine and the composition containing the imidazolidine to treatment and prevention of corneal neovascularization, corneal fibrosis, pterygium, meibomian gland dysfunction and visual fatigue.

Description

technical field [0001] The invention belongs to the technical field of treatment of ophthalmic diseases, and in particular relates to the use of mizoribine and a composition comprising mizoribine, and more specifically relates to the use of mizoribine and a composition comprising mizoribine for treating and preventing corneal neovascularization , corneal fibrosis, pterygium, meibomian gland dysfunction and visual fatigue. Background technique [0002] The normal cornea is a non-vascular transparent tissue with good light transmission and is an important refractive medium of the eye. Due to infection, inflammation, degeneration, trauma, limbal stem cell destruction and other reasons, new blood vessels often invade the cornea and affect the function of the cornea. Corneal neovascularization (CNV) is one of the most common blinding eye diseases in the world. Its pathogenesis is not yet fully understood. It is currently believed that the main causes of neovascularization are hy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K31/7056A61K47/02A61K47/18A61P27/02A61P27/10
CPCA61K31/7056A61K9/08A61K9/0048A61K47/02A61K47/186A61K47/18A61P27/02A61P27/10
Inventor 刘祖国林祥
Owner EYE MEDICAL XIAMEN BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap